实用中医药杂志2024,Vol.40Issue(6) :1087-1088.

参松养心胶囊辅治冠心病并心律失常临床观察

张欢
实用中医药杂志2024,Vol.40Issue(6) :1087-1088.

参松养心胶囊辅治冠心病并心律失常临床观察

张欢1
扫码查看

作者信息

  • 1. 河南省直第三人民医院调剂室,河南 郑州 450000
  • 折叠

摘要

目的:观察参松养心胶囊辅治冠心病并心律失常的疗效.方法:88例依据不同治疗方式分为对照组43例和观察组45例,两组均给予琥珀酸美托洛尔缓释片治疗,观察组加用参松养心胶囊治疗.结果:观察组总有效率高于对照组(P<0.05).治疗后两组血清PCT、CRP、IL-6水平低于治疗前(P<0.05),且观察组低于对照组(P<0.05).治疗后两组血浆比黏度、纤维蛋白原、血细胞比容水平低于治疗前(P<0.05),且观察组低于对照组(P<0.05).两组不良反应发生率比较无统计学意义(P>0.05).结论:参松养心胶囊辅治冠心病并心律失常可提高疗效,且安全.

Abstract

Objective:To observe the curative effect of Shensong Yangxin Capsule in the treatment of coronary heart disease and arrhythmia.Methods:Eighty-eight cases were divided into the control group(43 cases)and the observation group(45 cases)according to different treatment methods.Both groups were treated with metoprolol succinate sustained-release tablets and the observation group was treated with Shensong Yangxin Capsule in addition.Results:The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of serum PCT,CRP and IL-6 in the two groups were lower than those before treatment(P<0.05),and those in the observation group were lower than the control group(P<0.05).After treatment,the levels of plasma specific viscosity,fibrinogen and hematocrit in the two groups were lower than those before treatment(P<0.05),and those in the observation group were lower than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Shensong Yangxin Capsule could improve the curative effect in the treatment of coronary heart disease and arrhythmia,with safety.

关键词

冠心病/心律失常/参松养心胶囊/对照治疗观察

Key words

Coronary heart disease/Arrhythmia/Shensong Yangxin Capsule/Control treatment and observation

引用本文复制引用

出版年

2024
实用中医药杂志
重庆医科大学中医药学院

实用中医药杂志

影响因子:0.546
ISSN:1004-2814
段落导航相关论文